Martin Shkreli

An activist investor has announced building a significant, active position in Quantum Computing Inc. (QCLS), signaling a strong vote of confidence in the company's future. This presents an opportunity for investors to gain exposure to the high-growth quantum computing sector alongside influential involvement. A separate, high-risk opportunity exists with Capricor Therapeutics (CAPR), a biotech company with a major upcoming catalyst. The stock's value is tied to the FDA's decision on its Duchenne muscular dystrophy drug, Deremyocel, following the company's recent submission of positive trial data. A final FDA decision is targeted for around July of next year, creating a significant binary event for investors.

Consider a speculative short position on Capricor Therapeutics (CAPR), as there is high conviction that its upcoming clinical trial data will be negative, causing the stock to fall. A bullish outlook on Bitcoin (BTC) suggests a potential rally towards a $90,000 price target. Be aware that leveraged instruments like MicroStrategy (MSTR) simply amplify Bitcoin's volatility rather than providing a safer investment. A recent FDA retirement is viewed as a significant positive catalyst for Replimune (REPL), potentially clearing the path for its drug approval. For a longer-term holding, AstraZeneca (AZN) is a bet on its strong management to deliver an 11% annualized return by hitting its 2030 growth targets.

A primary bullish opportunity is in NVIDIA (NVDA), with a potential price target of $200 by year-end, accessible via $170 or $180 strike call options. Conversely, the entire quantum computing sector is presented as a high-conviction short, with expectations of a significant price collapse. Specific companies to consider shorting

Consider shorting the quantum computing sector, with IonQ (INQ) being a "favorite short" and BTQ being a "great short" with a price target of $1. For a high-risk speculative play, Abivax (ABVX) is viewed as a potential merger target with a speculative buyout price of $150 to $200. The analyst suggests buying Bitcoin (BTC) now, with a potential future price target of $88,000 to $90,000. A high-conviction long idea is Taiwan Semiconductor Manufacturing (TSM), which the analyst loves. While long-term bullish on NVIDIA (NVDA), the current market reaction suggests waiting for a better entry point.

Consider buying NVIDIA (NVDA) on a potential dip to the $185 to $190 range, capitalizing on its exceptionally strong earnings and accelerating growth in the AI sector. For short-term traders, a rally in NVDA to $200 or $205 could present a shorting opportunity based on "peak euphoria" and valuation concerns. Long-term investors should view NVDA as the primary "picks and shovels" play on the transformative AI super cycle, which is expanding beyond tech giants to enterprise and sovereign nations. Monitor the success of private firms like OpenAI and Anthropic as their demand for chips is a key leading indicator for NVIDIA's future performance. Avoid assuming the AI rally will lift all tech sectors, as the outlook for quantum computing is viewed with skepticism and is not expected to follow NVIDIA's trajectory.

Consider Agios Pharmaceuticals (AGIO) as a buying opportunity, as its recent 50% drop is seen as an overreaction, with its remaining assets potentially undervalued. For a bearish trade, consider shorting Olema Oncology (OLMA), based on the belief that its recent price spike was a temporary squeeze and the stock is likely to fall. The entire quantum computing sector is viewed as overhyped, with D-Wave Quantum (QBTS) specifically identified as a potential short sale candidate. Be cautious with NVIDIA (NVDA), as extremely high market expectations may prevent the stock from rallying even if it reports strong earnings. Another high-conviction bearish idea is shorting utility company Dominion Energy (D).

Consider the high-conviction biotech picks Spruce Biosciences (SPRB), Abivax (ABVX), and Sarepta (SRPT) for potential long-term investment. A strong bearish view is held on Olema Pharmaceuticals (OLMA), which is being actively shorted with a potential daily price target of $12. For a shorter-term trade, Palantir (PLTR) is favored for momentum trading on the long side. Leading up to its earnings report, NVIDIA (NVDA) is expected to beat estimates and raise future guidance. Lastly, despite its partnerships, IonQ (IONQ) is identified as a high-conviction shorting opportunity based on skepticism of its valuation.

Given a very bearish market outlook, the highest conviction opportunities are in shorting overvalued and speculative stocks. Consider shorting or buying puts on quantum computing stocks like IonQ (IONQ), which is seen as having a long way to fall, potentially to the $2 range. Similarly, D-Wave Quantum (QBTS) is viewed as a potential short candidate that could fall to $5. In biotech, Anavex Life Sciences (AVXL) is being shorted due to a recent drug rejection, with expectations of a significant price drop. Another high-conviction short is on BBAI, which is considered fundamentally weak and overvalued.